Sponsor
Ron Johnson
Senator · R-WI
Senator · R-WI
The bill expands clinician and hospital freedom to use off‑label and certain emergency therapies — potentially improving access for patients lacking approved options — but does so by weakening federal oversight and safety surveillance, which raises patient-safety, coordination, cost, and regulatory-consistency risks.
Patients with chronic or hard-to-treat conditions can gain faster access to additional therapies because clinicians may prescribe FDA-approved drugs for off‑label uses and hospitals can offer certain EUA/561B products without federal restriction.
Clinicians (doctors and other healthcare providers) have greater autonomy to make individualized treatment decisions without fear of federal restriction.
Hospitals and health systems can expand therapeutic offerings and potentially accelerate patient access during emergencies by using a broader set of therapies.
Patients — including Medicaid beneficiaries — face higher risk of ineffective or harmful treatments because reducing federal oversight could enable widespread off‑label use and weaken post‑market surveillance and safety communications.
Limits on FDA, CDC, and NIH authority could impede coordinated federal responses to emerging public‑health threats and reduce the government's ability to issue timely guidance or safety warnings.
State regulators, payers, insurers, and taxpayers could face higher costs if there is pressure to cover or reimburse off‑label uses that lack proven clinical benefit.
Based on analysis of 2 sections of legislative text.
Bars federal agencies and federal law from regulating medical practice or restricting prescriptions of FDA‑approved drugs for off‑label uses, while preserving federal limits on several specified sensitive practices.
Official title: Clarify that agencies of the Department of Health and Human Services do not have the authority to regulate the practice of medicine.
Introduced May 21, 2025 by Ron Johnson · Last progress May 21, 2025
Preempts federal authority over the practice of medicine and off‑label prescribing. It bars federal agencies (including FDA, NIH, CDC) and federal laws, rules, or policies from regulating clinical practice or restricting the prescription or dispensation of FDA‑approved drugs for unapproved uses, while explicitly preserving federal restrictions on abortion, assisted suicide/euthanasia, coercive family planning, female genital mutilation, and gender transition medical interventions. If enacted, the bill would remove federal oversight that limits or guides how clinicians prescribe approved medicines for uses not specifically approved by the FDA, shifting practical control over those decisions away from federal agencies and toward states, clinicians, patients, and other authorities.